このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Immuron 過去の業績

過去基準チェック /06

Immuronは3.1%の年平均成長率で業績を伸ばしているが、Biotechs業界はgrowingで12.4%毎年増加している。売上は減少しており、年平均7.6%の割合である。

主要情報

3.1%

収益成長率

12.8%

EPS成長率

Biotechs 業界の成長	9.6%
収益成長率	-7.6%
株主資本利益率	-22.1%
ネット・マージン	-108.5%
前回の決算情報	31 Dec 2023

Recent updates

収支内訳

Immuron の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

ASX:IMC 収益、費用、利益 ( )AUD Millions
日付	収益	収益	G+A経費	研究開発費
31 Dec 23	4	-4	6	4
30 Sep 23	3	-4	5	3
30 Jun 23	2	-4	5	3
31 Mar 23	1	-3	5	2
31 Dec 22	1	-3	4	2
30 Sep 22	1	-3	4	1
30 Jun 22	1	-3	4	1
31 Mar 22	1	-4	4	1
31 Dec 21	0	-4	4	1
30 Sep 21	0	-6	5	1
30 Jun 21	0	-8	6	1
31 Mar 21	1	-8	6	1
31 Dec 20	1	-7	6	1
30 Sep 20	2	-5	5	1
30 Jun 20	3	-3	4	1
31 Mar 20	3	-4	5	1
31 Dec 19	3	-5	6	1
30 Sep 19	3	-5	6	1
30 Jun 19	2	-5	6	1
31 Mar 19	2	-4	5	1
31 Dec 18	2	-3	4	1
30 Sep 18	2	-3	4	2
30 Jun 18	2	-3	4	2
31 Mar 18	2	-4	4	3
31 Dec 17	2	-5	5	4
30 Sep 17	2	-6	5	4
30 Jun 17	1	-7	5	5
31 Mar 17	1	-8	5	4
31 Dec 16	1	-6	5	4
30 Sep 16	1	-6	5	4
30 Jun 16	1	-7	5	4
31 Mar 16	1	-5	4	4
31 Dec 15	1	-4	3	4
30 Sep 15	1	-4	3	4
30 Jun 15	1	-3	2	3
31 Mar 15	1	-3	2	2
31 Dec 14	1	-2	1	2
30 Sep 14	1	-2	1	2
30 Jun 14	1	-2	2	1
31 Mar 14	1	-3	2	1
31 Dec 13	0	-3	2	1
30 Sep 13	0	-4	2	1

質の高い収益: IMCは現在利益が出ていません。

利益率の向上: IMCは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: IMCは利益を出していないが、過去 5 年間で年間3.1%の割合で損失を削減してきた。

成長の加速: IMCの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: IMCは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -2.6% ) と比較することは困難です。

株主資本利益率

高いROE: IMCは現在利益が出ていないため、自己資本利益率 ( -22.15% ) はマイナスです。

Immuron 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Full year 2023 earnings released: AU$0.017 loss per share (vs AU$0.013 loss in FY 2022)

Full year 2023 earnings released: AU$0.017 loss per share (vs AU$0.013 loss in FY 2022)

First half 2023 earnings released: AU$0.009 loss per share (vs AU$0.008 loss in 1H 2022)

Full year 2022 earnings released: AU$0.013 loss per share (vs AU$0.038 loss in FY 2021)

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings released: AU$0.038 loss per share (vs AU$0.017 loss in FY 2020)

Recent updates

Immuron Limited has filed a Follow-on Equity Offering in the amount of $2.069083 million.

Immuron Requests Pre-IND Meeting for IMM-529 with FDA Filing

Immuron Limited Appoints Jeannette Joughin as Director

Immuron Limited Announces Resignation of Roger Aston as Non-Executive Director

We're Not Very Worried About Immuron's (ASX:IMC) Cash Burn Rate

Immuron Limited Announces Positive Results Support Travelan Progress to Phase 3 Clinical Trials in the US

Immuron Limited Clinical Trials Update

Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study

Immuron Limited, Annual General Meeting, Nov 21, 2023

Immuron Limited Announces Travelan® Clinical Study Cohort 2 Commences

Full year 2023 earnings released: AU$0.017 loss per share (vs AU$0.013 loss in FY 2022)

Full year 2023 earnings released: AU$0.017 loss per share (vs AU$0.013 loss in FY 2022)

Immuron Limited Announces First Patients Enrolled in Travelan® Clinical Study

Immuron Limited Initiates Recruitment of Travelan Clinical Study

Immuron Limited Announces US Food and Drug Administration Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves Way for Clinical Trial Initiation

First half 2023 earnings released: AU$0.009 loss per share (vs AU$0.008 loss in 1H 2022)

Immuron US DoD Naval Medical Research Center Responds to FDA Clinical Hold for New Campylobacter ETEC Therapeutic

Immuron Limited Receives FDA Approval for Travelan IND Application

Immuron Limited Submits IND Application To FDA for Travelan

Insufficient new directors

Immuron Limited, Annual General Meeting, Oct 28, 2022

Full year 2022 earnings released: AU$0.013 loss per share (vs AU$0.038 loss in FY 2021)

Immuron Limited Provides Update on IMM-124E SARS-CoV-2 Research

Immuron Limited Provides Update on IND Application for Campylobacter ETEC Therapeutic

Immuron US DoD Naval Medical Research Center Submits IND Application for New Campylobacter ETEC Therapeutic

Immuron Limited Provides Update on the Planned Clinical Trial to Evaluate the Efficacy of Travelan and Two Third Party Non-Antibiotic Products in Travelers' Diarrhea

Immuron Limited Appoints Steven Lydeamore as Chief Executive Officer, effective June 27, 2022

Insufficient new directors

Immuron Limited Announces Work on the Investigational New Drug Application to Evaluate the Efficacy of A Single Dose Regimen of Travelan

First half 2022 earnings: Revenues and EPS in line with analyst expectations

We Think Immuron (ASX:IMC) Can Afford To Drive Business Growth

Full year 2021 earnings released: AU$0.038 loss per share (vs AU$0.017 loss in FY 2020)

Executive Vice Chairman Peter Anastasiou has left the company

We Think Immuron (ASX:IMC) Can Afford To Drive Business Growth

Insufficient new directors

Immuron Limited Provides Monash University Research Update on SARS-CoV-2 Program

We Think Immuron (ASX:IMC) Can Afford To Drive Business Growth

First half 2021 earnings released: AU$0.026 loss per share (vs AU$0.009 loss in 1H 2020)

Have Insiders Been Selling Immuron Limited (ASX:IMC) Shares This Year?

New 90-day low: AU$0.21

New 90-day low: AU$0.21

Immuron Limited Provides Update on Progress of the Anti-Viral Activity of IMM-124E

Immuron Limited Announces That the Naval Medical Research Center Has Completed the Characterisation of the Colostrum Harvested from Cows Immunized with the Experimental Vaccine Developed to Target Campylobacter and Enterotoxigenic E.Coli

Immuron Limited Announces US DoD NMRC Reports Positive Response to Vaccine

New 90-day low: AU$0.23

Immuron Limited Provides Shareholders and the Market with an Update on the Planned Clinical Programs in Travelers’ Diarrhea

Full year earnings released - AU$0.017 loss per share

Immuron Limited has completed a Follow-on Equity Offering in the amount of $20.000025 million.

New 90-day high - AU$0.85

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /06